Study:
Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder
Rationale:
Drugs used in chemotherapy work in different ways to stop tumor cells from
dividing so they stop growing or die. Combining more than one drug may kill more tumor
cells.
Purpose:
Randomized phase III trial to compare different combination chemotherapy regimens
in treating patients who have advanced bladder cancer.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Bladder Cancer |
Biological: filgrastim
Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: gemcitabine hydrochloride |
Phase 3 |
Verified by
Cancer and Leukemia Group B
June, 2011
Sponsored by: Cancer and Leukemia Group B
Information provided by: Cancer and Leukemia Group B
ClinicalTrials.gov identifier: NCT00014534
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Dean F. Bajorin, MD., Study Chair